.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Cerilliant
Mallinckrodt
McKinsey
Teva
UBS
Accenture
Boehringer Ingelheim
AstraZeneca
US Army
Cantor Fitzgerald

Generated: June 25, 2017

DrugPatentWatch Database Preview

Granisetron hydrochloride - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for granisetron hydrochloride and what is the scope of granisetron hydrochloride patent protection?

Granisetron hydrochloride
is the generic ingredient in four branded drugs marketed by Roche, Sandoz Inc, West-ward Pharms Int, Taro Pharm, Akorn Inc, Barr, Fresenius Kabi Usa, Mylan, Hikma Farmaceutica, Pediatrx, Sagent Strides, Sagent Agila, Cipla Ltd, Aurobindo Pharma Ltd, Apotex Inc, Dr Reddys Labs Ltd, Mylan Labs Ltd, Epic Pharma Llc, Bionpharma Inc, Teva Pharms Usa, Wockhardt Usa, Natco Pharma, Luitpold, Orchid Hlthcare, Teva Pharms, and Claris, and is included in forty-eight NDAs. There are two patents protecting this compound and three Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Granisetron hydrochloride has twenty-five patent family members in nineteen countries.

There are twenty-six drug master file entries for granisetron hydrochloride. Eighteen suppliers are listed for this compound.

Summary for Generic Name: granisetron hydrochloride

Tradenames:4
Patents:2
Applicants:26
NDAs:48
Drug Master File Entries: see list26
Suppliers / Packagers: see list18
Bulk Api Vendors: see list62
Clinical Trials: see list2,313
Patent Applications: see list2,379
Therapeutic Class:Antiemetics
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:granisetron hydrochloride at DailyMed

Pharmacology for Ingredient: granisetron hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Luitpold
GRANISETRON HYDROCHLORIDE
granisetron hydrochloride
INJECTABLE;INJECTION091274-001Sep 22, 2010APRXNoNo► Subscribe► Subscribe
Sandoz Inc
GRANISETRON HYDROCHLORIDE
granisetron hydrochloride
INJECTABLE;INJECTION078835-001Jun 30, 2008APRXNoNo► Subscribe► Subscribe
Teva Pharms Usa
GRANISETRON HYDROCHLORIDE
granisetron hydrochloride
INJECTABLE;INJECTION077963-001Jan 3, 2008APRXNoYes► Subscribe► Subscribe
Sagent Strides
GRANISETRON HYDROCHLORIDE
granisetron hydrochloride
INJECTABLE;INJECTION091136-001Apr 9, 2010APRXNoNo► Subscribe► Subscribe
Aurobindo Pharma Ltd
GRANISETRON HYDROCHLORIDE
granisetron hydrochloride
INJECTABLE;INJECTION204238-002Jul 6, 2016APRXNoNo► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: granisetron hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Roche
KYTRIL
granisetron hydrochloride
INJECTABLE;INJECTION020239-003Sep 17, 20044,886,808► Subscribe
Roche
KYTRIL
granisetron hydrochloride
INJECTABLE;INJECTION020239-004Mar 11, 19945,952,340► Subscribe
Roche
KYTRIL
granisetron hydrochloride
INJECTABLE;INJECTION020239-001Dec 29, 19934,886,808► Subscribe
Roche
KYTRIL
granisetron hydrochloride
TABLET;ORAL020305-001Mar 16, 19954,886,808► Subscribe
Roche
KYTRIL
granisetron hydrochloride
INJECTABLE;INJECTION020239-004Mar 11, 19944,886,808► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: granisetron hydrochloride

Country Document Number Estimated Expiration
African Regional IP Organization (ARIPO)9400626► Subscribe
Hong Kong1012237► Subscribe
Japan2006083190► Subscribe
Australia6377494► Subscribe
Canada2158354► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Daiichi Sankyo
McKinsey
McKesson
Novartis
Cipla
Baxter
AstraZeneca
Covington
QuintilesIMS
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot